<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05628870</url>
  </required_header>
  <id_info>
    <org_study_id>HRS-1358-I-101</org_study_id>
    <nct_id>NCT05628870</nct_id>
  </id_info>
  <brief_title>A Trial of HRS-1358 Tablets in Metastatic or Local Advanced Breast Cancer</brief_title>
  <official_title>A Single-arm, Open-label, Multi-center Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HRS-1358 Monotherapy in Patients With Metastatic or Locally Advanced Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong Suncadia Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong Suncadia Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to evaluate the safety and tolerability of HRS-1358 monotherapy&#xD;
      in patients with metastatic or locally advanced breast cancer in order to estimate the&#xD;
      Dose-Limiting Toxicity (DLT), Maximum Tolerated Dose (MTD) and select the Recommended Phase 2&#xD;
      Dose (RP2D).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">February 7, 2023</start_date>
  <completion_date type="Anticipated">June 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single arm study of HRS-1358</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limited Toxicities (DLTs)</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Number of participants with dose-limiting toxicities (DLTs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>up to 28 days</time_frame>
    <description>The Maximum tolerated dose of HRS-1358 monotherapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RP2D</measure>
    <time_frame>Change From Baseline at 28 days</time_frame>
    <description>select the Recommended Phase 2 Dose (RP2D) of HRS-1358</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of adverse events (AEs)/serious adverse events (SAEs)</measure>
    <time_frame>up to 30 days after the last dose</time_frame>
    <description>Incidence and severity of adverse events (AEs)/serious adverse events (SAEs) graded by Common Terminology Criteria for Adverse Events (CTCAE) v5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>0.5 hour before first dose of first treatment period to the 0.5 hour before first dose of fourth treatment period</time_frame>
    <description>PK parameters of multiple doses of HRS-1358 monotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>0.5 hour before first dose of first treatment period to the 0.5 hour before first dose of fourth treatment period</time_frame>
    <description>PK parameters of multiple doses of HRS-1358 monotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>0.5 hour before first dose of first treatment period to the 0.5 hour before first dose of fourth treatment period</time_frame>
    <description>PK parameters of multiple doses of HRS-1358 monotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss</measure>
    <time_frame>0.5 hour before first dose of first treatment period to the 0.5 hour before first dose of fourth treatment period</time_frame>
    <description>PK parameters of multiple doses of HRS-1358 monotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss</measure>
    <time_frame>0.5 hour before first dose of first treatment period to the 0.5 hour before first dose of fourth treatment period</time_frame>
    <description>PK parameters of multiple doses of HRS-1358 monotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss</measure>
    <time_frame>0.5 hour before first dose of first treatment period to the 0.5 hour before first dose of fourth treatment period</time_frame>
    <description>PK parameters of multiple doses of HRS-1358 monotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCss</measure>
    <time_frame>0.5 hour before first dose of first treatment period to the 0.5 hour before first dose of fourth treatment period</time_frame>
    <description>PK parameters of multiple doses of HRS-1358 monotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rac</measure>
    <time_frame>0.5 hour before first dose of first treatment period to the 0.5 hour before first dose of fourth treatment period</time_frame>
    <description>PK parameters of multiple doses of HRS-1358 monotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR) in participants</measure>
    <time_frame>Up to approximately 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (CBR) in participants</measure>
    <time_frame>Up to approximately 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) in participants</measure>
    <time_frame>Up to approximately 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) observed in participants</measure>
    <time_frame>Up to approximately 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>HRS-1358</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily oral dosages of HR-1358</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HRS-1358</intervention_name>
    <description>HRS-1358 will be administered daily orally in continuous dosing over 28-day cycles.</description>
    <arm_group_label>HRS-1358</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically diagnosis of local advanced or metastatic breast cancer&#xD;
&#xD;
          2. Women must be postmenopausal, or pre-/peri-menopausal women must be on ovarian&#xD;
             suppression&#xD;
&#xD;
          3. At least 1 line of endocrine therapy in the metastatic or advanced setting&#xD;
&#xD;
          4. ECOG performance status score: 0-1;&#xD;
&#xD;
          5. Adequate organ functions as defined&#xD;
&#xD;
          6. Ability to understand and voluntarily agrees to participate by giving written informed&#xD;
             consent for the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. the investigators judged that it was not suitable to endocrine therapy&#xD;
&#xD;
          2. patients with active brain metastasis (without medical control or with clinical&#xD;
             symptoms),&#xD;
&#xD;
          3. History of clinically significant cardiovascular or cerebrovascular diseases&#xD;
&#xD;
          4. The subject has one of many factors affecting oral „ÄÅabsorption, distribution,&#xD;
             metabolism and excretion of drugs&#xD;
&#xD;
          5. Active autoimmune diseases, History of immunodeficiency, including positive HIV serum&#xD;
             test result and other acquired or congenital immunodeficiency diseases, or history of&#xD;
             organ transplantation&#xD;
&#xD;
          6. Have received other similar drugs in the past;&#xD;
&#xD;
          7. Known history of allergy to HRS-1358 ingredients&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 17, 2022</study_first_submitted>
  <study_first_submitted_qc>November 17, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2022</study_first_posted>
  <last_update_submitted>February 27, 2023</last_update_submitted>
  <last_update_submitted_qc>February 27, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

